SC Therapeutics Launches REACH2 Clinical Trial to Evaluate Novel Disease-Modifying Therapy for Refractory Chronic Cough SC Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative therapies that target mechano-sensitive ion channels (MSCs) for the treatment of respiratory and cardiovascular diseases,…
CorVista Health Receives New AMA Category III CPT Code for AI-Powered Cardiovascular Diagnostic Technology CorVista Health has announced that the American Medical Association (AMA) has approved a new Category III Current Procedural Terminology (CPT®) code for its innovative artificial intelligence-powered…
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Candidate Fizurex™ Altasciences has announced the successful completion of a pivotal toxicology study for Steel Therapeutics Inc.’s lead investigational therapy, Fizurex™, marking an important step toward clinical development of a potential…
BRUKINSA Phase 3 Trial Shows Chemotherapy-Free Promise for Frontline Mantle Cell Lymphoma BeOne Medicines Ltd. has announced positive topline findings from its pivotal Phase 3 MANGROVE clinical trial, marking a significant milestone in the treatment of newly diagnosed mantle cell…
Biocytogen Secures Favorable Court Ruling in Patent Dispute, Reinforcing Confidence in Its RenNano® Technology Platform Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SSE: 688796; HKEX: 02315) has announced a significant legal victory following a first-instance civil judgment issued by the Shanghai Intellectual…
Genmab Reports Positive Phase 3 Results for Fixed-Duration Epcoritamab Combination in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Genmab A/S has announced positive topline results from its pivotal Phase 3 EPCORE DLBCL-4 clinical trial, demonstrating that a fixed-duration treatment regimen…
Roche Launches AXELIOS 1 Sequencing Platform to Advance Genomics Research with Innovative SBX Technology Roche has announced the commercial launch of AXELIOS 1, a next-generation sequencing platform powered by its innovative Sequencing by Expansion (SBX) technology. Designed to deliver an…
Epicrispr Biotechnologies Reports Promising Phase 1/2 Data Showing Increased Muscle Volume with EPI-321 in Patients with Facioscapulohumeral Muscular Dystrophy Epicrispr Biotechnologies, a clinical-stage biotechnology company focused on developing epigenetic therapies, has announced encouraging interim results from its ongoing Phase 1/2…
New Reproducibility Standard Set for Breast Imaging Biomarkers QT Imaging Holdings, Inc., a medical device company focused on advancing breast health through radiation-free imaging technology, has reported new data characterizing the repeatability and reproducibility of quantitative imaging biomarkers generated by…
DiaMedica Begins Phase 2 Clinical Evaluation of DM199 in Fetal Growth Restriction as First Patients Receive Treatment DiaMedica Therapeutics has reached an important clinical milestone in its effort to address serious pregnancy-related complications, announcing that the first two patients have…
Trace Neuroscience Launches Global Clinical Development Program for TRCN-1023 in ALS Trace Neuroscience, Inc., a biopharmaceutical company focused on advancing genomic medicine for people living with neurodegenerative diseases, has announced the start of its global clinical development program for TRCN-1023,…
Cataltheia Group Publishes Clinical Data Supporting Deseyne Contact Lens for Presbyopia in Optometry and Vision Science The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, have announced the publication of pivotal clinical data in Optometry and Vision Science…